Results 81 to 90 of about 1,991 (194)

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Biomedicines
Hypertrophic cardiomyopathy (HCM) is a heterogeneous group of heart muscle disorders that affects millions, with an incidence from 1 in 500 to 1 in 200. Factors such as genetics, age, gender, comorbidities, and environmental factors may contribute to the
Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk   +8 more
doaj   +1 more source

Myosin inhibitors for treatment of hypertrophic cardiomyopathy [PDF]

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:/ / Primary objective: To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction ...
Amin, Ahmad S, Asselbergs, Folkert W, Bezzina, Connie, Elliott, Perry M, Quill, Samuel, Schmidt, Amand F, van der Velden, Jolanda   +6 more
core  

Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease: From Molecular Pathophysiology to Personalized Medicine [PDF]

, 2023
Hypertrophic cardiomyopathy is a myocardial disease defined by an increased left ventricular wall thickness not solely explained by abnormal loading conditions.
Altobelli, Ippolita, Bakalakos, Athanasios, De Michele, Gianantonio, Diana, Gaetano, Elliott, Perry M, Falco, Luigi, Limongelli, Giuseppe, Lioncino, Michele, Monda, Emanuele, Palmiero, Giuseppe, Perna, Alessia, Rubino, Marta, Verrillo, Federica   +12 more
core  

Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

Nature Communications
Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin ...
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W. Schmidt, Hans-Joachim Knölker, Anne Houdusse   +8 more
doaj   +1 more source

Mavacamten depresses human atrial contractility in the same EC50% range as human ventricle [PDF]

, 2022
Coppini, Raffaele, Ferrantini, Cecilia, Pioner, Jose' Manuel, Piroddi, Nicoletta, Poggesi, Corrado, Querceto, Silvia, Scellini, Beatrice, Tesi, Chiara, Vitale, Giulia   +8 more
core   +1 more source

Hüpertroofiline kardiomüopaatia [PDF]

, 2022
Hüpertroofiline kardiomüopaatia (HKM) on üks kõige sagedasem pärilik südamelihase haigus. Haiguse puhul täheldatakse vasaku vatsakese seina paksenemist, mis ei ole põhjustatud kroonilisest rõhust tingitud ülekoormusest.
Piskoppel, Polina
core   +1 more source

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

Indian Heart Journal
Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).
Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ayman K. Awad   +6 more
doaj   +1 more source

Mavacamten

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y. Wu, Maria C. Reuter, Yuhe Xia, Isabel C. Alvarez, Mark V. Sherrid   +7 more
doaj   +1 more source

Mavacamten in Hypertrophic Cardiomyopathy: Unraveling Therapeutic Potential and Clinical Implications in Advancing Cardiovascular Medicine [PDF]

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypertrophy, often leading to various cardiovascular symptoms and complications.
Ankit Kumar, Prachi Pandey, Dilip Jangid, Sanjeevani Tyagi, Rahul Raj
core   +1 more source